The German-based company, HWI Group, specializes in providing drug development and regulatory support services for the pharmaceutical, biotech, and medtech industries. With over 30 years of experience and three sites in Ruelzheim, Frankfurt, and Appenweier, HWI Group offers a comprehensive service portfolio that includes product development, analytical development, quality control, manufacturing of clinical and market batches, drug safety, and GxP services. They also collaborate with network partners to support clinical and preclinical studies. HWI Group focuses on developing innovative and affordable drugs, particularly for poorly soluble small and large molecules. Their capabilities span various dosage forms and release types. In 2022, HWI Group was acquired by TentaConsult, although the terms of the transaction were not disclosed.